Browse Studies — Arctuva

Phase 3

A Phase 3, Randomized, Double-mask, Placebo-controlled Study With Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease…

Thyroid Eye Disease, TEDGraves Orbitopathy

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Sling Therapeutics, Inc.NCT07753603

Phase 3

A Phase III, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection Treatment in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.

Thyroid Eye Disease, TED

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Minghui Pharmaceutical (Hangzhou) LtdNCT07622121

Phase 3

A Phase III, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection Treatment in Subjects With Active Moderate to Severe Thyroid Eye Disease.

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.

Thyroid Eye Disease, TED

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Minghui Pharmaceutical (Hangzhou) LtdNCT07622108